BMS to Sell API Site to S. Korean CDMO

Jun 20, 2017

Irish Times

Bristol-Myers Squibb will sell its active pharmaceutical ingredients manufacturing facility in Swords, Co Dublin to SK Biotek, a south Korean biotechnology firm.

The facility manufactures ingredients for a number of meds including BMS' blockbuster drug, Eliquis, used to lower the risk of stroke by blood clot.

SK Biotek will operate the plant as a standalone contract development manufacturing organization and will continue to manufacture the current portfolio of small molecule pharmaceutical products at the site.  The CDMO also intends to add marketing, R&D talent, and invest in upgrades to bring additional capacity to the site.

The companies plan to complete the deal by the fourth quarter 2017

Read the Irish Times coverage

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments